REMAP-CAP [COVID-19] [UPH]
Research type
Research Study
Full title
Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia
IRAS ID
237150
Contact name
Anthony Gordon
Contact email
Sponsor organisation
University Medical Centre Utrecht
Eudract number
2015-002340-14
ISRCTN Number
ISRCTN67000769
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
Universal Trial number, U1111-1189-1653
Duration of Study in the UK
3 years, 1 months, 31 days
Research summary
The aim of this trial is to determine the best range of treatments for patients who become severely ill due to COVID-19. Patients admitted to the Intensive Care Unit (ICU) with severe illnesses normally receive a combination of many different treatments to help them recover. For example, there are a number of different possible drugs to fight the coronavirus but patients also require treatment to help their breathing, circulation and kidneys. REMAP-CAP has many recruiting sites around the world and aims to enrol thousands of patients in more than 100 ICUs in the UK. The trial is designed to flexible and adaptive. Each hospital will choose which treatments to make available to patients from those available within the trial. Currently the trial is evaluating different anti-viral drugs (Lopinavir-Ritonavir and hydroxychloroquine), steroids to reduce inflammation and treatments which act on the immune system, often used to treat other conditions such as rheumatoid arthritis, (interferon-ß1a, anakinra, tocilizumab and sarilumab). The trial will look at how these drugs work in combination. Additional treatments will be added over time. Information will be reviewed regularly and, dependent upon the results, the trial will allocate more patients to the treatments that seem to be the most effective. Information is available at https://www.remapcap.org/. [COVID-19 amendment - 03/04/2020]
REC name
London - Surrey Borders Research Ethics Committee
REC reference
18/LO/0660
Date of REC Opinion
26 Apr 2018
REC opinion
Favourable Opinion